GEN Exclusives

More »

GEN News Highlights

More »
Jan 27, 2012

Roche, Technoclone Partner to Develop Coagulation Assays

  • Roche is partnering with Technoclone on the co-development of a range of coagulation assays. Technoclone is a reagent specialist in thrombosis and cardiovascular diagnostics. Roche says the collaboration will support its plan to develop a new line of analyzers marketed under the Cobas® brand for central coagulation laboratories. The firm projects introducing new instrumentation in the U.S. and Canada in 2014.

    “The expansion of the reagent menu into key areas of hemostasis will greatly enhance the new line of laboratory coagulation analyzers in development and will open up new opportunities for research related to targeted treatment and personalized healthcare,” comments Randy Pritchard, vp for marketing at Roche Diagnostics.

    The new deal with Technoclone follows on from last month’s announcement that Roche was buying platelet-function test specialist Verum Diagnostica for €11 million. At the time Roche said the acquisition will allow it to provide a comprehensive coagulation portfolio, ranging from self-monitoring applications to products for hospital and commercial laboratories.

    According to the Swiss drug giant, laboratory coagulation is estimated to be the fifth largest market in professional diagnostics worldwide. It was worth some $1.4 billion in sales during 2010 and has a projected annual growth rate of 5.1% over the next five years.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »